Welcome to CDC Stacks | Unlocking Proteomic Heterogeneity in Complex Diseases through Visual Analytics - 31674 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Unlocking Proteomic Heterogeneity in Complex Diseases through Visual Analytics
Filetype[PDF - 1.54 MB]

  • Pubmed ID:
  • Pubmed Central ID:
  • Description:
    Despite years of preclinical development, biological interventions designed to treat complex diseases such as asthma often fail in phase III clinical trials. These failures suggest that current methods to analyze biomedical data might be missing critical aspects of biological complexity such as the assumption that cases and controls come from homogeneous distributions. Here we discuss why and how methods from the rapidly evolving field of visual analytics can help translational teams (consisting of biologists, clinicians, and bioinformaticians) to address the challenge of modeling and inferring heterogeneity in the proteomic and phenotypic profiles of patients with complex diseases. Because a primary goal of visual analytics is to amplify the cognitive capacities of humans for detecting patterns in complex data, we begin with an overview of the cognitive foundations for the field of visual analytics. Next, we organize the primary ways in which a specific form of visual analytics called networks has been used to model and infer biological mechanisms, which help to identify the properties of networks that are particularly useful for the discovery and analysis of proteomic heterogeneity in complex diseases. We describe one such approach called subject-protein networks, and demonstrate its application on two proteomic datasets. This demonstration provides insights to help translational teams overcome theoretical, practical, and pedagogical hurdles for the widespread use of subject-protein networks for analyzing molecular heterogeneities, with the translational goal of designing biomarker-based clinical trials, and accelerating the development of personalized approaches to medicine.

  • Document Type:
  • Collection(s):
  • Funding:
    1UL1TR000071/TR/NCATS NIH HHS/United States
    HHSN268201000037C/HV/NHLBI NIH HHS/United States
    HHSN268201000037C-0-0-1/PHS HHS/United States
    KL2 TR000072/TR/NCATS NIH HHS/United States
    R21 OH009441/OH/NIOSH CDC HHS/United States
    R21OH009441-01A2/OH/NIOSH CDC HHS/United States
    UL1 TR000071/TR/NCATS NIH HHS/United States
No Related Documents.
You May Also Like: